

ROPEG-PV

Observational study on the use of ropeginterferon alfa-2b in polycythemia vera

Contatti: Monia Marchetti, monia.marchetti@uniupo.it

Trattamento: ropeginterferon alfa-2b

Sindromi MIELOPROLIFERATIVE CRONICHE target: Polycythemia Vera

Criteri Inclusione:

1. Patients diagnosed with Polycythemia Vera by WHO 2016
2. Patient aged ≥ 18 years old
3. Patients in need of cytoreductive treatments with ropeginterferon alfa-2b in first or later lines according to the reimbursability criteria defined by the Italian National Health System
4. Patients who have signed the written informed consent for study participation.